Study · Randomized controlled trial · 2021

14 results

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.

Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, Svane MS, Bandholm T, Bojsen-Møller KN, Blond MB, Jensen JB, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS

The New England journal of medicine1 May 2021Cited by 417 (Europe PMC)

PMID33951361DOI10.1056/nejmoa2028198PepBankPUB-33951361

Publisher page PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity after a low-calorie diet, liraglutide led to greater weight loss than placebo at 1 year (difference -6.8 kg).
In plain wordsIn adults with obesity, liraglutide helped keep off more weight than placebo after one year.
Peptide
Liraglutide
Outcome
DecreaseBody weight change vs placebo
Study
n: not reported in source
Comparator
Placebo plus usual activity
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg per day · 1 yearAs given in this study (human).
Measurements
Difference in body weight vs placebo
−6.8 kg
liraglutide group
Source sentences
Summary
in the liraglutide group, -6.8 kg (95% CI, -10.4 to -3.1; P<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
Report a problemFND-3395136101
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity, exercise plus liraglutide decreased body-fat percentage by 3.9 points, about twice the decrease with exercise alone (-1.7 points).
In plain wordsIn adults with obesity, adding liraglutide to exercise cut body fat about twice as much as exercise alone.
Peptide
Liraglutide
Outcome
DecreaseBody-fat percentage change, combination vs exercise
Study
n: not reported in source
Comparator
Exercise plus placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg per day · 1 yearAs given in this study (human).
Measurements
Change in body-fat percentage
−3.9 percentage points
combination group
Change in body-fat percentage
−1.7 percentage points
exercise group
Source sentences
Summary
The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (-1.7 percentage points; 95% CI, -3.2 to -0.2; P = 0.02) and the liraglutide group (-1.9 percentage points; 95% CI, -3.3 to -0.5; P = 0.009).
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
Report a problemFND-3395136105
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity, adding liraglutide to exercise led to greater weight loss than exercise alone (difference -5.4 kg).
In plain wordsIn adults with obesity, adding liraglutide to exercise led to more weight loss than exercise alone.
Peptide
Liraglutide
Outcome
DecreaseBody weight change, combination vs exercise
Study
n: not reported in source
Comparator
Exercise plus placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg per day · 1 yearAs given in this study (human).
Measurements
Difference in body weight vs exercise
−5.4 kg
combination group
Source sentences
Summary
The combination strategy led to greater weight loss than exercise (difference, -5.4 kg; 95% CI, -9.0 to -1.7; P = 0.004)
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
Report a problemFND-3395136103
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide alone was not among the strategies associated with improvement in glycated hemoglobin; only exercise plus liraglutide was.
In plain wordsIn adults with obesity, liraglutide alone was not linked to better long-term blood sugar; only exercise plus liraglutide was.
Peptide
Liraglutide
Outcome
No significant changeHbA1c with liraglutide alone
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3.0 mg per day · 1 yearAs given in this study (human).
Source sentences
Summary
Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness.
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
Report a problemFND-3395136110
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide alone was not among the strategies associated with improvement in insulin sensitivity; only exercise plus liraglutide was.
In plain wordsIn adults with obesity, liraglutide alone was not linked to better insulin sensitivity; only exercise plus liraglutide was.
Peptide
Liraglutide
Outcome
No significant changeInsulin sensitivity with liraglutide alone
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3.0 mg per day · 1 yearAs given in this study (human).
Source sentences
Summary
Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness.
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
Report a problemFND-3395136111
06HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide alone was not among the strategies associated with improvement in cardiorespiratory fitness; only exercise plus liraglutide was.
In plain wordsIn adults with obesity, liraglutide alone was not linked to better fitness; only exercise plus liraglutide was.
Peptide
Liraglutide
Outcome
No significant changeCardiorespiratory fitness with liraglutide alone
Study
n: not reported in source
Outcome group
Exercise and physical function · Cardiovascular
Studied dose
3.0 mg per day · 1 yearAs given in this study (human).
Source sentences
Summary
Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness.
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
Report a problemFND-3395136112
07HumanRandomized controlled trialSafety outcome
In adults with obesity, increased heart rate was observed more often in the liraglutide group than in the combination group.
In plain wordsIn adults with obesity, a raised heart rate occurred more often with liraglutide alone than with the combination.
Peptide
Liraglutide
Outcome
IncreaseIncreased heart rate
Study
n: not reported in source
Comparator
Exercise plus liraglutide combination
Outcome group
Adverse events · Cardiovascular
Studied dose
3.0 mg per day · 1 yearAs given in this study (human).
Source sentences
Summary
Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group.
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
Report a problemFND-3395136113
08HumanRandomized controlled trialSafety outcome
In adults with obesity, cholelithiasis was observed more often in the liraglutide group than in the combination group.
In plain wordsIn adults with obesity, gallstones occurred more often with liraglutide alone than with the combination.
Peptide
Liraglutide
Outcome
IncreaseCholelithiasis
Study
n: not reported in source
Comparator
Exercise plus liraglutide combination
Outcome group
Adverse events · Gastrointestinal
Studied dose
3.0 mg per day · 1 yearAs given in this study (human).
Source sentences
Summary
Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group.
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
Report a problemFND-3395136114

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

09HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity after a low-calorie diet, exercise plus liraglutide led to greater weight loss than placebo at 1 year (difference -9.5 kg).
In plain wordsIn adults with obesity, exercise plus liraglutide helped keep off more weight than placebo after one year.
Peptide
Liraglutide
Outcome
DecreaseBody weight change, combination vs placebo
Study
n: not reported in source
Comparator
Placebo plus usual activity
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Difference in body weight vs placebo
−9.5 kg
combination group
Source sentences
Summary
in the combination group, -9.5 kg (95% CI, -13.1 to -5.9; P<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3395136102
10HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, exercise plus liraglutide decreased body-fat percentage by 3.9 points, about twice the decrease with liraglutide alone (-1.9 points).
In plain wordsIn adults with obesity, adding exercise to liraglutide cut body fat about twice as much as liraglutide alone.
Peptide
Liraglutide
Outcome
DecreaseBody-fat percentage change, combination vs liraglutide
Study
n: not reported in source
Comparator
Liraglutide plus usual activity
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Measurements
Change in body-fat percentage
−3.9 percentage points
combination group
Change in body-fat percentage
−1.9 percentage points
liraglutide group
Source sentences
Summary
The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (-1.7 percentage points; 95% CI, -3.2 to -0.2; P = 0.02) and the liraglutide group (-1.9 percentage points; 95% CI, -3.3 to -0.5; P = 0.009).
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3395136106
11HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, exercise plus liraglutide did not lead to significantly greater weight loss than liraglutide alone (difference -2.7 kg).
In plain wordsIn adults with obesity, adding exercise to liraglutide did not clearly give more weight loss than liraglutide alone.
Peptide
Liraglutide
Outcome
No significant changeBody weight change, combination vs liraglutide
Study
n: not reported in source
Comparator
Liraglutide plus usual activity
Outcome group
Body weight · Metabolic and weight
Measurements
Difference in body weight vs liraglutide
−2.7 kg
combination group
Source sentences
Summary
but not liraglutide (-2.7 kg; 95% CI, -6.3 to 0.8; P = 0.13).
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3395136104
12HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, only the exercise plus liraglutide strategy was associated with improvement in glycated hemoglobin.
In plain wordsIn adults with obesity, only exercise plus liraglutide, not the other strategies, was linked to better long-term blood sugar.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness.
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3395136107
13HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, only the exercise plus liraglutide strategy was associated with improvement in insulin sensitivity.
In plain wordsIn adults with obesity, only exercise plus liraglutide, not the other strategies, was linked to better insulin sensitivity.
Peptide
Liraglutide
Outcome
IncreaseInsulin sensitivity
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness.
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3395136108
14HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, only the exercise plus liraglutide strategy was associated with improvement in cardiorespiratory fitness.
In plain wordsIn adults with obesity, only exercise plus liraglutide, not the other strategies, was linked to better fitness.
Peptide
Liraglutide
Outcome
IncreaseCardiorespiratory fitness
Study
n: not reported in source
Outcome group
Exercise and physical function · Cardiovascular
Source sentences
Summary
Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness.
1 context sentence(design, population, supporting numbers)
Summary · context
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus lira…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3395136109

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 4NCT07154719

GLP-1R Actions on Muscle and the Skeleton

Pennington Biomedical Research Centern = 509 Oct 2025 to est. 1 May 2027

Musculoskeletal Abnormalities · Obesity · Sarcopenic Obesity · Osteoporosis · Drug Effect

Trial page ClinicalTrials.govUpdated 27 Aug 2026

RecruitingNot applicableNCT06885736

LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy

Dasman Diabetes Instituten = 2327 Aug 2025 to est. 31 Dec 2029

Obesity

Trial page ClinicalTrials.govUpdated 21 Apr 2026

CompletedPhase 4NCT05574439

Young Adults With Early-onset Obesity Treated With Semaglutide

Signe Torekovn = 24630 May 2022 to 1 Apr 2026

Obesity, Adolescent

Trial page ClinicalTrials.govUpdated 8 Jul 2026

Status unknownPhase 4NCT04122716

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet

Signe Torekovn = 215Sept 2016 to est. Nov 2021

Obesity

Trial page ClinicalTrials.govUpdated 2 Nov 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.